The development or exacerbation of eating disorder symptoms after topiramate initiation

Jocelyn Lebow, Jeffrey A. Chuy, Kyle Cedermark, Katlyn Cook, Leslie A. Sim

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The Food and Drug Administration recently approved topiramate for migraine prevention in adolescents. Given the well-established appetite-suppressant side effects of topiramate, as well as data suggesting a potential comorbidity between migraine and eating disorders, susceptible young migraine patients may be at a greater risk for the development or worsening of eating disorder symptoms with topiramate therapy. This case series comprises 7 adolescent patients in whom serious eating disorders developed or were exacerbated after the initiation of topiramate therapy. Clinical characteristics of these patients are highlighted. In addition, this case series provides guidelines for providers to use in assessing eating disorders before prescribing topiramate for migraine prevention in adolescents.

Original languageEnglish (US)
Pages (from-to)e1312-e1316
JournalPediatrics
Volume135
Issue number5
DOIs
StatePublished - May 1 2015

Fingerprint

Migraine Disorders
Appetite Depressants
United States Food and Drug Administration
Comorbidity
topiramate
Feeding and Eating Disorders
Guidelines
Therapeutics

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Medicine(all)

Cite this

Lebow, J., Chuy, J. A., Cedermark, K., Cook, K., & Sim, L. A. (2015). The development or exacerbation of eating disorder symptoms after topiramate initiation. Pediatrics, 135(5), e1312-e1316. https://doi.org/10.1542/peds.2014-3413

The development or exacerbation of eating disorder symptoms after topiramate initiation. / Lebow, Jocelyn; Chuy, Jeffrey A.; Cedermark, Kyle; Cook, Katlyn; Sim, Leslie A.

In: Pediatrics, Vol. 135, No. 5, 01.05.2015, p. e1312-e1316.

Research output: Contribution to journalArticle

Lebow, J, Chuy, JA, Cedermark, K, Cook, K & Sim, LA 2015, 'The development or exacerbation of eating disorder symptoms after topiramate initiation', Pediatrics, vol. 135, no. 5, pp. e1312-e1316. https://doi.org/10.1542/peds.2014-3413
Lebow, Jocelyn ; Chuy, Jeffrey A. ; Cedermark, Kyle ; Cook, Katlyn ; Sim, Leslie A. / The development or exacerbation of eating disorder symptoms after topiramate initiation. In: Pediatrics. 2015 ; Vol. 135, No. 5. pp. e1312-e1316.
@article{9221feb4216243209430c8280c85c7db,
title = "The development or exacerbation of eating disorder symptoms after topiramate initiation",
abstract = "The Food and Drug Administration recently approved topiramate for migraine prevention in adolescents. Given the well-established appetite-suppressant side effects of topiramate, as well as data suggesting a potential comorbidity between migraine and eating disorders, susceptible young migraine patients may be at a greater risk for the development or worsening of eating disorder symptoms with topiramate therapy. This case series comprises 7 adolescent patients in whom serious eating disorders developed or were exacerbated after the initiation of topiramate therapy. Clinical characteristics of these patients are highlighted. In addition, this case series provides guidelines for providers to use in assessing eating disorders before prescribing topiramate for migraine prevention in adolescents.",
author = "Jocelyn Lebow and Chuy, {Jeffrey A.} and Kyle Cedermark and Katlyn Cook and Sim, {Leslie A.}",
year = "2015",
month = "5",
day = "1",
doi = "10.1542/peds.2014-3413",
language = "English (US)",
volume = "135",
pages = "e1312--e1316",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "5",

}

TY - JOUR

T1 - The development or exacerbation of eating disorder symptoms after topiramate initiation

AU - Lebow, Jocelyn

AU - Chuy, Jeffrey A.

AU - Cedermark, Kyle

AU - Cook, Katlyn

AU - Sim, Leslie A.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - The Food and Drug Administration recently approved topiramate for migraine prevention in adolescents. Given the well-established appetite-suppressant side effects of topiramate, as well as data suggesting a potential comorbidity between migraine and eating disorders, susceptible young migraine patients may be at a greater risk for the development or worsening of eating disorder symptoms with topiramate therapy. This case series comprises 7 adolescent patients in whom serious eating disorders developed or were exacerbated after the initiation of topiramate therapy. Clinical characteristics of these patients are highlighted. In addition, this case series provides guidelines for providers to use in assessing eating disorders before prescribing topiramate for migraine prevention in adolescents.

AB - The Food and Drug Administration recently approved topiramate for migraine prevention in adolescents. Given the well-established appetite-suppressant side effects of topiramate, as well as data suggesting a potential comorbidity between migraine and eating disorders, susceptible young migraine patients may be at a greater risk for the development or worsening of eating disorder symptoms with topiramate therapy. This case series comprises 7 adolescent patients in whom serious eating disorders developed or were exacerbated after the initiation of topiramate therapy. Clinical characteristics of these patients are highlighted. In addition, this case series provides guidelines for providers to use in assessing eating disorders before prescribing topiramate for migraine prevention in adolescents.

UR - http://www.scopus.com/inward/record.url?scp=84929484011&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929484011&partnerID=8YFLogxK

U2 - 10.1542/peds.2014-3413

DO - 10.1542/peds.2014-3413

M3 - Article

C2 - 25847809

AN - SCOPUS:84929484011

VL - 135

SP - e1312-e1316

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 5

ER -